New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SCCO;NVS;MOS;ADM;IP From The Last 14 Days
Check below for free stories on SCCO;NVS;MOS;ADM;IP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 14, 2014
14:42 EDTNVSAlnylam slips after Novartis reportedly cuts back RNAi development
Subscribe for More Information
11:48 EDTNVSNovartis significantly reducing RNAi development efforts, FierceBiotech says
Subscribe for More Information
April 9, 2014
12:04 EDTADM, MOSU.S. corn exports projected to increase 125M bushels
Subscribe for More Information
10:06 EDTIPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:15 EDTIPInternational Paper initiated with an Outperform at Credit Suisse
Subscribe for More Information
07:09 EDTNVSReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
April 8, 2014
14:34 EDTIPInternational Paper acquires remaining shares of Orsa IP Embalagens
International Paper has acquired the remaining 25% of shares of Orsa International Paper Embalagens S.A. from its joint venture partner, Brazilian pulp and packaging producer Jari Celulose, Embalagens e Papel S.A. The shares were purchased at the original transaction price per share for ~$135MM. With this transaction, International Paper takes full ownership of three containerboard mills and four box plants, which made up Jari's former corrugated packaging assets. "This investment is in-line with our strategy to selectively grow our industrial packaging business globally in attractive markets and put capital to work that deliver returns above our cost of capital," said CEO John Faraci.
07:22 EDTNVSCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
April 7, 2014
07:27 EDTNVSAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
05:32 EDTNVSNovartis Bexsero vaccine receives FDA Breakthrough Therapy designation
Novartis announced that Bexsero, Meningococcal Group B Vaccine, has received a Breakthrough Therapy designation from the FDA. Bexsero is already approved in Europe, Canada and Australia to help protect against invasive meningococcal disease caused by serogroup B. Novartis plans to file for U.S. licensure of Bexsero as early as Q2; exact timing will depend on guidance from the FDA. This is the fourth Breakthrough Therapy designation for Novartis, underscoring leadership in developing innovative therapies and vaccines. This announcement comes on the heels of a landmark decision from regulators in the UK, where the Joint Committee on Vaccination and Immunisation recommended the inclusion of Bexsero in the country's National Immunisation Programme for routine use in infants from two months of age.
April 4, 2014
13:12 EDTMOSCanpotex announces agreement with Indian customers
Canpotex announced that it has agreed to an annual contract with its government and private sector partners in India to supply approximately 1 million tonnes of potash at a price of $322.00 per tonne on a CFR basis. Dechka also confirmed that Canpotex intends to expand its market development programs in India in future to help provide Indian farmers with the educational and other tools needed to improve yields through balanced fertilization and best management practices. Canpotex is the exclusive offshore marketing company owned by the three Saskatchewan potash producing companies: Agrium (AGU), Mosaic (MOS), and Potash Corporation of Saskatchewan (POT).
07:51 EDTADMArcher Daniels price target raised to $50 from $45 at Citigroup
Citigroup raised its price target for Archer Daniels shares to $50 after meeting with management and keeps a Buy rating on the stock. Citi said it has increased conviction that ADM's main businesses are building positive momentum.
April 3, 2014
08:06 EDTNVSApricus Biosciences granted national phase approval for Vitaros in Luxembourg
Apricus Biosciences (APRI) announced that the Ministry of Health of Luxembourg has granted national phase approval to Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction. The company has now received a total of nine national phase approvals for Vitaros®, including Luxembourg, Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom following its broad approval by European health authorities in June 2013. Apricus has an exclusive commercialization partnership in place with Hexal AG, an affiliate within the Sandoz Division of the Novartis (NVS), for the commercialization of Vitaros in several European countries, including Luxembourg.
06:26 EDTNVSNovartis placing temporary moratorium on all IIT funding in Japan
Subscribe for More Information
06:26 EDTNVSNovartis announces third-party internal review of IITs
06:25 EDTNVSNovartis appoints Dirk Koshce as head of Novartis Pharmaceuticals
Subscribe for More Information
06:05 EDTMOSMosaic implied volatility of 21 at lower end of index mean range
Subscribe for More Information
05:31 EDTNVSNovartis says data on 19 investigational compounds to be presented
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research. Among the data being presented are single agent and combination studies with key investigational compounds in the Novartis Oncology breast cancer development program, including an early phase study of the CDK4/6 inhibitor LEE011 and PI3K inhibitors BKM120 and BYL719. LEE011 and BKM120 are currently in Phase III and BYL719 is in Phase I trials for the treatment of advanced breast cancer.
April 2, 2014
10:53 EDTMOSAgrium slips after warning on late planting season impact on earnings
Shares of agricultural nutrients producer Agrium (AGU) are slipping after the company warned that it expects first quarter earnings per share just above breakeven. WHAT'S NEW. Agrium announced that the late spring season this year is expected to result in first quarter earnings per share just above breakeven, while analysts' consensus estimate prior to the announcement stood at 53c per share. The company said the slow start to the spring season is expected to impact the timing of its wholesale, and to a lesser extent its retail, earnings. First quarter wholesale results were also impacted by reduced rail availability and the usual lag in realized wholesale nutrient prices, Agrium added. Additionally, the Carseland nitrogen facility experienced a failure in March, which has resulted in an unplanned shutdown to make repairs that are expected to be complete in the second half of May. The shutdown is anticipated to lower product availability of urea by approximately 100,000 tonnes and ammonia by approximately 20,000 tonnes in the second quarter, Agrium noted. WHAT'S NOTABLE: On February 20, Agrium said that it expected FY14 North American spring crop area to be near FY13. It said that it projected crop nutrient shipments to be strong in the first half of FY14, in part due to a shorter fall application season in FY13 due to weather. Agrium projected North American nitrogen demand to decline about 2%-4% in FY13/FY14 due primarily to reduced corn acreage, while global nitrogen demand is projected to increase by 1.5%-2% in FY14 from FY13 levels. OTHERS TO WATCH: Agrium's peers in the fertilizer industry include Mosaic (MOS) and Potash (POT). PRICE ACTION: During morning trading, shares of Agrium fell 1.76% to $95.80, Potash dropped 1.6%, and Mosaic slipped 0.7%.
06:34 EDTNVSNovartis price target raised to $93 from $88 at Leerink
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use